Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?
作者： Helen J Nye , William G Herrington , None
DOI: 10.1159/000323739
关键词:
摘要: Metformin is the first-line oral agent in treatment of type 2 diabetes and has many established benefits, including reduction macrovascular complications diabetes. Its prescription pa
sci-hub.se 参考文章(10)
Nancy C. Sambol, Janie Chiang, Emil T. Lin, Anita M. Goodman, Chui Y. Liu, Leslie Z. Benet, Martin G. Cogan, Kidney Function and Age Are Both Predictors of Pharmacokinetics of Metformin The Journal of Clinical Pharmacology. ,vol. 35, pp. 1094- 1102 ,(1995) , 10.1002/J.1552-4604.1995.TB04033.X
Dean T Eurich, Finlay A McAlister, David F Blackburn, Sumit R Majumdar, Ross T Tsuyuki, Janice Varney, Jeffrey A Johnson, Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review BMJ. ,vol. 335, pp. 497- 497 ,(2007) , 10.1136/BMJ.39314.620174.80
A. M. E. Stades, J. T. Heikens, D. W. Erkelens, F. Holleman, J. B. L. Hoekstra, Metformin and lactic acidosis: cause or coincidence? A review of case reports Journal of Internal Medicine. ,vol. 255, pp. 179- 187 ,(2004) , 10.1046/J.1365-2796.2003.01271.X
J. D. Lalau, J. M. Race, Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'. Diabetes, Obesity and Metabolism. ,vol. 3, pp. 195- 201 ,(2001) , 10.1046/J.1463-1326.2001.00128.X
M. Bodmer, C. Meier, S. Krahenbuhl, S. S. Jick, C. R. Meier, Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. ,vol. 31, pp. 2086- 2091 ,(2008) , 10.2337/DC08-1171
Shari Bolen, Leonard Feldman, Jason Vassy, Lisa Wilson, Hsin-Chieh Yeh, Spyridon Marinopoulos, Crystal Wiley, Elizabeth Selvin, Renee Wilson, Eric B. Bass, Frederick L. Brancati, Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine. ,vol. 147, pp. 386- 399 ,(2007) , 10.7326/0003-4819-147-6-200709180-00178
M. K. Mani, Metformin in renal failure—weigh the evidence Nephrology Dialysis Transplantation. ,vol. 24, pp. 2287- 2288 ,(2009) , 10.1093/NDT/GFP197
C. J. Currie, C. D. Poole, E. A. M. Gale, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia. ,vol. 52, pp. 1766- 1777 ,(2009) , 10.1007/S00125-009-1440-6
C A Cull, A Neil, Matthews, S E Manley, R R Holman, I M Stratton, H McElroy, E Kohner, R C Turner, C Fox, D Hadden, D Wright, Grp Ukpds., V Frighi, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) The Lancet. ,vol. 352, pp. 854- 865 ,(1998)
Michael Gnant, CA Cull, SE Manley, RR Holman, UK Prospective Diabetes, IM Stratton, Matthews, R Turner, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. The Lancet. ,(1998)